A study of Abemaciclib, and CDK 4/6 inhibitor, in combination with Fulvestrant compared to chemotherapy in women with HR positive, HER2 negative advanced breast cancer with visceral metastases (I3Y-MC-JPCU)

A study of Abemaciclib, and CDK 4/6 inhibitor, in combination with Fulvestrant compared to chemotherapy in women with HR positive, HER2 negative advanced breast cancer with visceral metastases (I3Y-MC-JPCU)

Trial Category:
Breast
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Nebraska Cancer Specialists, Omaha, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members